Rare leptin disorder patients gain access to experimental drug
NCT ID NCT04710056
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program provides expanded access to REGN4461 (mibavademab) for people with rare diseases caused by deficient leptin signaling, such as generalized lipodystrophy and monogenic obesity. The drug aims to help control metabolic issues linked to these conditions. Participants receive the medication outside of a formal clinical trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- REGN4461 (mibavademab)
- What this could lead to
- If it works, this could help control metabolic complications in people with rare leptin-signaling disorders.
- What could go wrong
- This is an expanded access program, not a formal trial, so evidence on safety and effectiveness is limited. Benefits may vary and risks are not fully known.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GENERALIZED LIPODYSTROPHY (GLD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple breakfast replace the glucose drink for diabetes testing?
- New dissolvable implant shows promise for smoothing wrinkles
- Rare fat disorder gene hunt: just 2 patients could unlock answers
- Scientists probe Fat-Immune link in rare and common metabolic diseases
- HIV Meds' hidden impact on heart and body fat revealed
- Breakfast showdown: High-Fat vs. High-Carb – which worsens blood fats?